Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

被引：1
作者：
Mian, Agrima [1 ]
Wei, Wei [2 ]
Hamilton, Betty K. [3 ]
Winter, Allison M. [3 ]
Khouri, Jack [3 ]
Pohlman, Brad [3 ]
Gerds, Aaron T. [3 ]
Jagadeesh, Deepa [3 ]
Anwer, Faiz [3 ]
Kalaycio, Matt [3 ]
Dean, Robert M. [3 ]
Sobecks, Ronald [3 ]
Caimi, Paolo F. [3 ]
Hill, Brian T. [3 ]
Majhail, Navneet S. [4 ]
机构：
[1] Cleveland Clin, Dept Internal Med, Cleveland, OH USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA
[3] Cleveland Clin, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH USA
[4] Sarah Cannon, Nashville, TN 37203 USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / 05期
关键词：
TRANSPLANTATION; OUTCOMES; THERAPY;
D O I：
10.1038/s41409-023-01934-4
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：590 / 593
页数：4
相关论文
共 50 条
  • [31] Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
    Westin, Jason R.
    Locke, Frederick L.
    Dickinson, Michael
    Ghobadi, Armin
    Elsawy, Mahmoud
    van Meerten, Tom
    Miklos, David B.
    Ulrickson, Matthew L.
    Perales, Miguel-Angel
    Farooq, Umar
    Wannesson, Luciano
    Leslie, Lori
    Kersten, Marie Jose
    Jacobson, Caron A.
    Pagel, John M.
    Wulf, Gerald
    Johnston, Patrick
    Rapoport, Aaron P.
    Du, Linqiu
    Vardhanabhuti, Saran
    Filosto, Simone
    Shah, Jina
    Snider, Julia T.
    Cheng, Paul
    To, Christina
    Oluwole, Olalekan O.
    Sureda, Anna
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1894 - 1905
  • [32] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) : 45 - 56
  • [33] Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China
    Li, Na
    Zheng, Bin
    Cai, Hongfu
    Yang, Ting
    Hong, Yunda
    Liu, Maobai
    Hu, Jianda
    SUPPORTIVE CARE IN CANCER, 2022, 30 (07) : 6113 - 6121
  • [34] An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States
    Oluwole, Olalekan O.
    Patel, Anik R.
    Vadgama, Sachin
    Smith, Nathaniel J.
    Blissett, Rob
    Feng, Chaoling
    Dickinson, Michael
    Johnston, Patrick B.
    Perales, Miguel-Angel
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 77 - 83
  • [35] Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma
    Halford, Zachery
    Anderson, Mary Kate
    Bennett, Lunawati L.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (03) : 390 - 405
  • [36] Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
    Locke, Frederick L.
    Siddiqi, Tanya
    Jacobson, Caron A.
    Ghobadi, Armin
    Ahmed, Sairah
    Miklos, David B.
    Perales, Miguel -Angel
    Munoz, Javier
    Fingrut, Warren B.
    Pennisi, Martina
    Gauthier, Jordan
    Shadman, Mazyar
    Gowda, Lohith
    Mirza, Abu-Sayeef
    Abid, Muhammad Bilal
    Hong, Sanghee
    Majhail, Navneet S.
    Kharfan-Dabaja, Mohamed A.
    Khurana, Arushi
    Badar, Talha
    Lin, Yi
    Bennani, N. Nora
    Herr, Megan M.
    Hu, Zhen-Huan
    Wang, Hai -Lin
    Baer, Anjani
    Baro, Elande
    Miao, Harry
    Spooner, Clare
    Xu, Hairong
    Pasquini, Marcelo C.
    BLOOD, 2024, 143 (26) : 2722 - 2734
  • [37] Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
    Iacoboni, Gloria
    Villacampa, Guillermo
    Martinez-Cibrian, Nuria
    Bailen, Rebeca
    Lopez Corral, Lucia
    Sanchez, Jose M.
    Guerreiro, Manuel
    Carolina Caballero, Ana
    Mussetti, Alberto
    Sancho, Juan-Manuel
    Hernani, Rafael
    Abrisqueta, Pau
    Solano, Carlos
    Sureda, Anna
    Briones, Javier
    Martin Garcia-Sancho, Alejandro
    Kwon, Mi
    Luis Reguera-Ortega, Juan
    Barba, Pere
    CANCER MEDICINE, 2021, 10 (10): : 3214 - 3223
  • [38] Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
    Faramand, Rawan
    Jain, Michael
    Staedtke, Verena
    Kotani, Hiroshi
    Bai, Renyuan
    Reid, Kayla
    Lee, Sae Bom
    Spitler, Kristen
    Wang, Xuefeng
    Cao, Biwei
    Pinilla, Javier
    Lazaryan, Aleksander
    Khimani, Farhad
    Shah, Bijal
    Chavez, Julio C.
    Nishihori, Taiga
    Mishra, Asmita
    Mullinax, John
    Gonzalez, Ricardo
    Hussaini, Mohammad
    Dam, Marian
    Brandjes, Brigett D.
    Bachmeier, Christina A.
    Anasetti, Claudio
    Locke, Frederick L.
    Davila, Marco L.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4823 - 4831
  • [39] Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review
    Wu, XiaoQin
    Zhang, XinYue
    Xun, RenDe
    Liu, MengSi
    Sun, Zhen
    Huang, JianChao
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [40] Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective
    Yang, Hongbo
    Hao, Yanni
    Chai, Xinglei
    Qi, Cynthia Z.
    Wu, Eric Q.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 1016 - 1024
12345